Back

Plasma natriuretic peptide level is an independent determinant of major clinical outcomes in atrial fibrillation patients without heart failure: The Fushimi AF Registry

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Atrial Fibrillation-Related Stroke: the Features Worth Clinician’s Attention Clinical ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Yasuhiro Hamatani

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Temporal relationship between atrial fibrillation and ischaemic stroke in a large cohort with continuous rhythm monitoring
Doctor D. Singer (Boston, US)
Abstract Slides
Presentation thumbnail
Relationship of aging and incident comorbidities to stroke risk in 594,169 Patients with atrial fibrillation: a nationwide analysis
Professor L. Fauchier (Tours, FR)
Abstract Slides
Presentation thumbnail
Atrial fibrillation burden and the risks of ischemic stroke and intracranial hemorrhage: comparisons of catheter ablation, medical therapy, and non-atrial fibrillation population
Doctor M. Kim (Seoul, KR)
Abstract Slides
Presentation thumbnail
Risk of ischemic stroke in patients with acute myocardial infarction and new atrial fibrillation: a nationwide analysis
Professor L. Fauchier (Tours, FR)
Abstract Slides
Presentation thumbnail
The effect of body mass index on clinical outcomes in patients with newly diagnosed atrial fibrillation in the GARFIELD-AF registry
Doctor C. Camm (Oxford, GB)
Abstract Slides

Access the full session

Session thumbnail
Atrial Fibrillation-Related Stroke: the Features Worth Clinician’s Attention

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Congress Presentation
Interactive discussion and Q&A
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - discussion
thumbnail
Congress Presentation
Oral anticoagulation in subclinical atrial fibrillation: pro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources